Study 1 (NCT 00123253) This study re-randomized 207 HIV-infected patients with lipodystrophy who completed a 2 mg dose of EGRIFTA (1 mg/vial formulation) treatment in the Main Phase to receive either EGRIFTA (N=154) or placebo (N=50) for an additional 26-week duration (3:1 randomization ratio)
In the research space, combining a Growth Hormone-Releasing Hormone (GHRH) with a Growth Hormone Secretagogue Receptor (GHSR) agonist is a highly studied mechanism
Goal: Support lean-mass gains, reductions in adipose tissue and improved metabolic function by raising IGF-1
J Egypt Soc Nephrol Transplant
Various compounds are considered as possible alternatives to titanium dioxide, such as binary oxides (ZnO, Cu 2 O, WO 3 , V 2 O 5 , Bi 2 O 3 , Fe(III) oxides and hydroxides, niobium oxides, Ta 2 O 5 , ZrO 2 , CeO 2 , and Ga 2 O 3 ), binary sulfides (CdS, ZnS, Bi 2 S 3 , MoS 2 , and Sb 2 S 3 ), ternary oxides (vanadates, Bi 2 WO 6 , Bi 2 MO 6 , ZnWO 4 , CdWO 4 , PbWO 4 , Zn 2 SnO 4 , Pb 2 Sn 2 O 6 , indates, gallates, antimonates, bismutates, titanates, ferrites, and niobates), bismuth oxyhalides, indium hydroxides, quaternary oxides, and quaternary oxyhalides (Di et al
